Kingswood Wealth Advisors LLC Has $1.50 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Kingswood Wealth Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 90.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,906 shares of the biopharmaceutical company’s stock after purchasing an additional 10,412 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,503,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in GILD. Private Wealth Management Group LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Sachetta LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $30,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. Finally, Gladius Capital Management LP bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.3 %

NASDAQ:GILD traded down $0.19 during trading hours on Wednesday, reaching $74.00. The company had a trading volume of 4,212,741 shares, compared to its average volume of 7,380,036. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The firm has a market cap of $92.19 billion, a price-to-earnings ratio of 206.61, a P/E/G ratio of 3.37 and a beta of 0.18. The business’s 50-day simple moving average is $69.18 and its two-hundred day simple moving average is $70.49. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on GILD shares. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a report on Monday, July 8th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research note on Wednesday, April 24th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Finally, TD Cowen dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $81.81.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.